AusperBio to Unveil Groundbreaking Clinical Data Updates at EASL Congress 2024
AusperBio Therapeutics Inc. and Ausper Biopharma Co., Ltd. are set to present groundbreaking clinical data updates on their molecule AHB-137 at the EASL™ Congress 2024. The Phase I trials focus on achieving a functional cure for chronic hepatitis B, a prevalent liver disease affecting millions globally. Learn more about the innovative research efforts at the official EASL™ Congress website.
CRISPR Technology: Revolutionizing Medicine and Healthcare
The approval of the world’s first CRISPR therapy to treat sickle cell disease and beta-thalassemia patients signifies a significant milestone in the field of gene editing. CRISPR technology has potential applications in targeting and treating various types of cancer, combating AIDS, addressing cystic fibrosis, muscular dystrophy, Huntington’s disease, blood disorders, and even COVID-19. As CRISPR technology continues to advance, its potential applications in medicine and healthcare are expanding, offering new avenues for personalized medicine.
Kimer Med Secures $1.3 Million Contract for Antiviral Drug Development
Kimer Med, a biotech startup in New Zealand, has secured a $1.3 million contract to advance antiviral drug development. The focus is on developing new antiviral drug candidates for the treatment of alphaviruses, which can cause significant human and animal disease. Kimer Med has shown progress in developing antivirals with efficacy against various viruses, including Dengue and Zika.
Tharimmune, Inc. to Showcase Groundbreaking Innovations at 2024 Emerging Growth Conference
Tharimmune, Inc. is set to present its groundbreaking innovations at the 2024 Emerging Growth Conference, showcasing its advancements in inflammation and immunology therapies. The event offers a platform for Tharimmune to engage with the investment community and highlight its commitment to addressing challenging medical conditions.